Company Watch

Zydus Cadila receives tentative approval for Carvedilol Tablets

Our News Bureau - Ahmedabad

Zydus Cadila has received tentative approval from the USFDA to market Carvedilol Tablets 3.125 mg, 6.25 mg, 12.5 mg and 25 mg, for the US market. The drug falls in the cardiovascular segment. The current sales of Carvedilol Tablets in the US market, as per NDC Health, is estimated at $ 1.24 billion.

The group had recently received the tentative approval to market Sertraline Hydrochloride Tablets, 25 mg, 50 mg and 100 mg, in the US market through its US subsidiary, Zydus Pharmaceuticals, USA. So far, the group has filed 30 ANDAs and 35 DMFs.